Ar­se­nal­Bio lands $70M cash deal with can­cer gi­ant Genen­tech to de­vel­op cell ther­a­py

San Fran­cis­co-based Ar­se­nal­Bio’s de­sign­er T cells pro­gram is at­tract­ing the at­ten­tion of some big play­ers.

Af­ter clos­ing a deal and grab­bing $70 mil­lion in cash from Bris­tol My­ers Squibb last year, the com­pa­ny is back in the news with a brand new deal, this time with Genen­tech.

Ar­se­nal­Bio will re­ceive $70 mil­lion up­front from Genen­tech along with re­search sup­port, the com­pa­nies an­nounced Tues­day. Un­der the col­lab­o­ra­tion, both com­pa­nies will share re­search ideas and de­vel­op tar­get­ed T cells for sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER